Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 10130600

    Lipid scavenging in Ras cancers

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10130659

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10132810

    Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor

    Nektar Therapeutics · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10130658

    Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound

    Provectus Pharmatech, Inc. · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 2018326059

    COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

    GANYMED PHARMACEUTICALS AG [DE] · Granted Thu Nov 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Nov 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10117852

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10118938

    Arsenoplatin anti-cancer agents

    Northwestern University · Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10117947

    Virus-like particle conjugates for diagnosis and treatment of tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10111878

    N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer

    Agios Pharmaceuticals, Inc. · Granted Tue Oct 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10111861

    Treatment of breast cancer

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Oct 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10111871

    Nanoparticle drug delivery system and method of treating cancer and neurotrauma

    Northwestern University · Granted Tue Oct 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10105436

    Smallpox vaccine for cancer treatment

    Calidi Biotherapeutics, Inc. · Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10107816

    G-protein coupled receptor-associated diagnostics and therapeutics for B-cell chronic lymphocytic leukemia

    The Regents of the University of California · Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10100083

    Leukemia stem cell targeting ligands and methods of use

    The Regents of the University of California · Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. WO 2018184678

    INHIBITEUR DES HDAC EN ASSOCIATION AVEC UN INHIBITEUR D'INTERACTION VEGF/VEGFR DESTINÉ À UN TRAITEMENT CONTRE LE CANCER BASÉ SUR LA NUMÉRATION PLAQUETTAIRE

    4SC AG [DE] · Granted Thu Oct 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10080739

    Aryl imidazoles and their use as anti-cancer agents

    APTOSE BIOSCIENCES INC. · Granted Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10081668

    Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10076520

    Use of tyrosine kinase inhibitor in cancer treatment

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10077296

    Methods and compositions for the treatment and prevention of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10071945

    Nuclear receptor modulators and their use for the treatment and prevention of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10072084

    Dual specific immunotoxin for brain tumor therapy

    The United States of America as Represented by the Secretary Department of Health and Human Services (NIH) · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10064964

    Compounds and methods for the detection of TRPV-6 cancers and drug delivery

    Soricimed Biopharma Inc. · Granted Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10064923

    Therapeutic cancer vaccines derived from a novel dendritic cell line

    DCPRIME B.V. · Granted Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10058587

    Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity

    Soricimed Biopharma Inc. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10052393

    Multifunctional nanomaterials for the treatment of cancer

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10052382

    Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides

    The United States of America as Represented by the Secretary of Health (NIH) · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10053494

    Chemically activated nanocapsid functionalized for cancer targeting

    The Regents of the University of California · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10052371

    Compositions and methods for treatment of cancer using bacteria

    Decoy Biosystems, Inc. · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10047401

    Expression protein-coding and noncoding genes as prognostic classifiers in early stage lung cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10039775

    Preparation method for antitumor drug AP26113

    Suzhou Miracpharma Technology Co., Ltd. · Granted Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10039725

    Method for treating non-melanoma skin cancer by inducing UDP-glucuronosyltransferase activity using pterostilbene

    The Regents of the University of California · Granted Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10036751

    Method of evaluating glioblastoma multiforme patient applicable to immunotherapy treatment based on dendritic cell tumor vaccines and method of prognosticating survival rate in glioblastoma mulztiforme patient after treatment

    China Medical University Hospital · Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10035981

    Kidney-specific tumor vaccine directed against kidney tumor antigen G-250

    The Regents of the University of California · Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10028911

    Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

    Pacira Pharmaceuticals, Inc. · Granted Tue Jul 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10022325

    Compositions and methods for the treatment of cancer

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10022364

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10023588

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10023637

    Combination immunotherapy for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10023652

    Method of targeting glycoproteins to treat cancer

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10023650

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10023916

    Markers of tumor cell response to anti-cancer therapy

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10016484

    Methods of treating lung cancer

    Five Prime Therapeutics, Inc. · Granted Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10016480

    Peptide-based methods for treating pancreatic cancer

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10012653

    Nanoparticles for targeting acid tumor microenvironments

    The Board of Regents of the University of Texas System · Granted Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10001483

    Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10001485

    Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor

    The Regents of the University of California · Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10000813

    Method of diagnosing and treating cancer using B-catenin splice variants

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9993449

    (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

    Northwestern University · Granted Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.